Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review

References

• Wu H, Huang M, Cao P, et al. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther. 2012;13(5):281–288. doi:10.4161/cbt.18943
   PubMed Web of Science ®Google Scholar
• Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30(2):88–106. doi:10.3109/08977194.2012.660936
   PubMed Web of Science ®Google Scholar
• Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta Rev Cancer. 2014;1845(2):136–154.
   PubMed Web of Science ®Google Scholar
• Vigneswara V, Kundi S, Ahmed Z. Receptor tyrosine kinases: molecular switches regulating CNS axon regeneration. J Signal Transduct. 2012;2012:1–14
   Google Scholar
• Lohi O, Lehto V-P. STAM/EAST/Hbp adapter proteins–integrators of signalling pathways. FEBS Lett. 2001;508(3):287–290. doi:10.1016/S0014-5793(01)03079-4
   PubMed Web of Science ®Google Scholar
• Park S-Y, Lee C-J, Choi J-H, et al. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. J Exp Clin Cancer Res. 2019;38(1):1–18. doi:10.1186/s13046-019-1405-7
   PubMed Web of Science ®Google Scholar
• Thomas S, Snowden J, Zeidler M, et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113(3):365–371. doi:10.1038/bjc.2015.233
   PubMed Web of Science ®Google Scholar
• Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–2629. doi:10.4049/jimmunol.178.5.2623
   PubMed Web of Science ®Google Scholar
• von Manstein V, Min Yang C, Richter D, et al. Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther. 2013;8(3):193–202. doi:10.2174/1574362409666140206221931
   PubMed Web of Science ®Google Scholar
• Argetsinger LS, Kouadio J-LK, Steen H, et al. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol. 2004;24(11):4955–4967. doi:10.1128/MCB.24.11.4955-4967.2004
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang L, Wu Y, et al. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway. Toxicology. 2013;304:120–131. doi:10.1016/j.tox.2012.12.018
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol. 2005;5(8):593–605. doi:10.1038/nri1667
   PubMed Web of Science ®Google Scholar
• Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells. 2001;19(5):378–387. doi:10.1634/stemcells.19-5-378
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of JAK–STAT signalling in the immune system. Nat Rev Immunol. 2003;3(11):900–911. doi:10.1038/nri1226
   PubMed Web of Science ®Google Scholar
• Laouar Y, Welte T, Fu X-Y, et al. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19(6):903–912. doi:10.1016/S1074-7613(03)00332-7
   PubMed Web of Science ®Google Scholar
• Huang LJ-S, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8(6):1327–1338. doi:10.1016/S1097-2765(01)00401-4
   PubMed Web of Science ®Google Scholar
• Zhang Z, Mao H, Du X, et al. Correction: a novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway. Oncotarget. 2016;7(49):81972. doi:10.18632/oncotarget.13803
   PubMedGoogle Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. doi:10.1038/nrc2734
   PubMed Web of Science ®Google Scholar
• Groner B, von Manstein V. Jak Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017;451:1–14. doi:10.1016/j.mce.2017.05.033
   PubMed Web of Science ®Google Scholar
• Harada D, Takigawa N, Kiura K. The role of STAT3 in non-small cell lung cancer. Cancers. 2014;6(2):708–722. doi:10.3390/cancers6020708
   PubMed Web of Science ®Google Scholar
• Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007;251(2):199–210. doi:10.1016/j.canlet.2006.10.017
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Cao L, et al. Inhibition of autophagy potentiates the anti‐metastasis effect of phenethyl isothiocyanate through JAK2/STAT3 pathway in lung cancer cells. Mol Carcinog. 2018;57(4):522–535. doi:10.1002/mc.22777
   PubMed Web of Science ®Google Scholar
• Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1(1):46–54. doi:10.1038/35094059
   PubMed Web of Science ®Google Scholar
• Chen X, Ying Z, Lin X, et al. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest. 2013;123(6):2576–2589. doi:10.1172/JCI68143
   PubMed Web of Science ®Google Scholar
• Alicea-Velazquez NL, Boggon TJ. The use of structural biology in Janus kinase targeted drug discovery. Curr Drug Targets. 2011;12(4):546–555. doi:10.2174/138945011794751528
   PubMed Web of Science ®Google Scholar
• Liu JF, Deng WW, Chen L, et al. Inhibition of JAK2/STAT3 reduces tumor‐induced angiogenesis and myeloid‐derived suppressor cells in head and neck cancer. Mol Carcinog. 2018;57(3):429–439. doi:10.1002/mc.22767
   PubMed Web of Science ®Google Scholar
• Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs. 2005;16(6):601–607. doi:10.1097/00001813-200507000-00002
   PubMed Web of Science ®Google Scholar
• Lee H, Pal SK, Reckamp K, et al. STAT3: a target to enhance antitumor immune response. Cancer Immunol Immunother. 2010;2010:41–59.
   Web of Science ®Google Scholar
• McLoughlin RM, Jenkins BJ, Grail D, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Nat Acad Sci. 2005;102(27):9589–9594. doi:10.1073/pnas.0501794102
   PubMed Web of Science ®Google Scholar
• Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19(1):1–11. doi:10.1128/MCB.19.1.1
   PubMed Web of Science ®Google Scholar
• Munoz J, Dhillon N, Janku F, et al. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014;19(5):536. doi:10.1634/theoncologist.2013-0407
   PubMed Web of Science ®Google Scholar
• Sun K-X, Xia H-W, Xia R-L. Anticancer effect of salidroside on colon cancer through inhibiting JAK2/STAT3 signaling pathway. Int J Clin Exp Pathol. 2015;8(1):615.
   PubMed Web of Science ®Google Scholar
• Wu J, Guo J, Cao Q, et al. Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway. Oncol Lett. 2017;13(2):770–776. doi:10.3892/ol.2016.5476
   PubMed Web of Science ®Google Scholar
• Sun L, Hu L, Cogdell D, et al. MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway. Autophagy. 2017;13(4):703–714. doi:10.1080/15548627.2017.1280217
   PubMed Web of Science ®Google Scholar
• Pokhriyal R, Hariprasad R, Kumar L, et al. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019;11:1179299X19860815. doi:10.1177/1179299X19860815
   PubMedGoogle Scholar
• Tan HF, Putoczki LT, Stylli SS, et al. The role of STAT3 signaling in mediating tumor resistance to cancer therapy. Curr Drug Targets. 2014;15(14):1341–1353. doi:10.2174/1389450115666141120104146
   PubMed Web of Science ®Google Scholar
• Real PJ, Sierra A, de Juan A, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21(50):7611–7618. doi:10.1038/sj.onc.1206004
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–170. doi:10.1056/NEJMra1202117
   PubMed Web of Science ®Google Scholar
• Mukthavaram R, Ouyang X, Saklecha R, et al. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. J Transl Med. 2015;13(1):1–10. doi:10.1186/s12967-015-0627-5
   PubMed Web of Science ®Google Scholar
• Jin Y, Kim Y, Lee Y-J, et al. Natural products targeting STAT3 signaling pathways in cancer cells. Biodesign. 2016;4:1–17.
   Google Scholar
• Qiao H, Zhao D, Shi H, et al. Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3. Oncol Rep. 2015;34(4):1875–1882. doi:10.3892/or.2015.4140
   PubMed Web of Science ®Google Scholar
• Li X, Jia L, Lu X, et al. Dihydroartemisinin is a newly defined STAT3 inhibitor that may be of multiple potential uses in cancer treatment. Cancer Cell Microenviron. 2016;3:1.
   Google Scholar
• Darvin P, Baeg SJ, Joung YH, et al. Tannic acid inhibits the Jak2/STAT3 pathway and induces G1/S arrest and mitochondrial apoptosis in YD-38 gingival cancer cells. Int J Oncol. 2015;47(3):1111–1120. doi:10.3892/ijo.2015.3098
   PubMed Web of Science ®Google Scholar
• Guo D, Wang C, Wang Q, et al. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget. 2017;8(24):39640. doi:10.18632/oncotarget.17387
   PubMedGoogle Scholar
• Laklai H, Miroshnikova YA, Pickup MW, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22(5):497–505. doi:10.1038/nm.4082
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71(14):5020–5029. doi:10.1158/0008-5472.CAN-11-0908
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Ma Y, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005;25(17):7432–7440. doi:10.1128/MCB.25.17.7432-7440.2005
   PubMed Web of Science ®Google Scholar
• Loncle C, Bonjoch L, Folch-Puy E, et al. IL17 functions through the novel REG3β–JAK2–STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer. Cancer Res. 2015;75(22):4852–4862. doi:10.1158/0008-5472.CAN-15-0896
   PubMed Web of Science ®Google Scholar
• Rabi T, Catapano CV. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells. Tumor Biol. 2016;37(9):12455–12464. doi:10.1007/s13277-016-5102-2
   PubMedGoogle Scholar
• Wörmann SM, Song L, Ai J, et al. Loss of P53 function activates JAK2–STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival. Gastroenterology. 2016;151(1):180–93. e12. doi:10.1053/j.gastro.2016.03.010
   PubMed Web of Science ®Google Scholar
• Girisa S, Shabnam B, Monisha J, et al. Potential of zerumbone as an anti-cancer agent. Molecules. 2019;24(4):734. doi:10.3390/molecules24040734
   PubMed Web of Science ®Google Scholar
• Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci. 2007;12(12):5039–5051. doi:10.2741/2446
   PubMed Web of Science ®Google Scholar
• Wang S, Chen X, Tang M. MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2. Oncol Rep. 2014;32(6):2824–2830. doi:10.3892/or.2014.3478
   PubMed Web of Science ®Google Scholar
• Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20(20):2499–2513. doi:10.1038/sj.onc.1204349
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee WS, Jeong J, et al. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget. 2015;6(37):40158. doi:10.18632/oncotarget.5522
   PubMedGoogle Scholar
• Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24–stem cell–like breast cancer cells in human tumors. J Clin Invest. 2011;121(7):2723–2735. doi:10.1172/JCI44745
   PubMed Web of Science ®Google Scholar
• Zhu D, Shen Z, Liu J, et al. The ROS-mediated activation of STAT-3/VEGF signaling is involved in the 27-hydroxycholesterol-induced angiogenesis in human breast cancer cells. Toxicol Lett. 2016;264:79–86. doi:10.1016/j.toxlet.2016.11.006
   PubMed Web of Science ®Google Scholar
• Siddiquee KAZ, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18(2):254–267. doi:10.1038/cr.2008.18
   PubMed Web of Science ®Google Scholar
• Li GX, Tiulim JW, Lang JE, et al. Inflammatory breast cancer: diagnostic, molecular and therapeutic considerations. Curr Breast Cancer Rep. 2019;11(4):335–346. doi:10.1007/s12609-019-00337-z
   Web of Science ®Google Scholar
• Ferrand A, Kowalski-Chauvel A, Bertrand C, et al. Involvement of JAK2 upstream of the PI 3-kinase in cell–cell adhesion regulation by gastrin. Exp Cell Res. 2004;301(2):128–138. doi:10.1016/j.yexcr.2004.07.037
   PubMed Web of Science ®Google Scholar
• Nightingale J, Patel S, Suzuki N, et al. Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. J Am Soc Nephrol. 2004;15(1):21–32. doi:10.1097/01.ASN.0000102479.92582.43
   PubMed Web of Science ®Google Scholar
• Liu X, Ji Q, Ye N, et al. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE 2 mediated JAK2/STAT3 signaling pathway. PLoS One. 2015;10(5):e0123478. doi:10.1371/journal.pone.0123478
   PubMed Web of Science ®Google Scholar
• Liu K, Gao H, Wang Q, et al. Hispidulin suppresses cell growth and metastasis by targeting PIM 1 through JAK 2/STAT 3 signaling in colorectal cancer. Cancer Sci. 2018;109(5):1369–1381. doi:10.1111/cas.13575
   PubMed Web of Science ®Google Scholar
• Lu YM, Chen W, Zhu JS, et al. Eriocalyxin B blocks human SW1116 colon cancer cell proliferation, migration, invasion, cell cycle progression and angiogenesis via the JAK2/STAT3 signaling pathway. Mol Med Rep. 2016;13(3):2235–2240. doi:10.3892/mmr.2016.4800
   PubMed Web of Science ®Google Scholar
• Li N, Mao D, Cao Y, et al. Downregulation of SIRT6 by miR-34c-5p is associated with poor prognosis and promotes colon cancer proliferation through inhibiting apoptosis via the JAK2/STAT3 signaling pathway. Int J Oncol. 2018;52(5):1515–1527. doi:10.3892/ijo.2018.4304
   PubMed Web of Science ®Google Scholar
• Lin TE, HuangFu W-C, Chao M-W, et al. A novel selective JAK2 inhibitor identified using pharmacological interactions. Front Pharmacol. 2018;9:1379. doi:10.3389/fphar.2018.01379
   PubMed Web of Science ®Google Scholar
• Seo J-M, Park S, Kim J-H. Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. J Biol Chem. 2012;287(17):13840–13849. doi:10.1074/jbc.M111.317131
   PubMed Web of Science ®Google Scholar
• Chen M-W, Yang S-T, Chien M-H, et al. The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res. 2017;77(8):1955–1967. doi:10.1158/0008-5472.CAN-16-1115
   PubMed Web of Science ®Google Scholar
• Pan J-X, Ding K, Wang C-Y. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012;31(4):178. doi:10.5732/cjc.011.10290
   PubMedGoogle Scholar
• YoshikawaT,MiyamotoM,AoyamaT,etal.JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett. 2018; 15(4):5772–5780. doi: 10.3892/ol.2018.8028
   Google Scholar
• Yoshikawa T, Miyamoto M, Aoyama T, et al. JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett. 2018;15(4):5772–5780. doi:10.3892/ol.2018.8028
   PubMed Web of Science ®Google Scholar
• Benabbou N, Mirshahi P, Cadillon M, et al. Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line. Int J Oncol. 2013;43(3):685–694. doi:10.3892/ijo.2013.2017
   PubMed Web of Science ®Google Scholar
• Zhang W, Lei C, Fan J, et al. miR-18a promotes cell proliferation of esophageal squamous cell carcinoma cells by increasing cyclin D1 via regulating PTEN-PI3K-AKT-mTOR signaling axis. Biochem Biophys Res Commun. 2016;477(1):144–149. doi:10.1016/j.bbrc.2016.06.034
   PubMed Web of Science ®Google Scholar
• Peng H-Y, Cheng Y-C, Hsu Y-M, et al. MPT0B098, a microtubule inhibitor, suppresses JAK2/STAT3 signaling pathway through modulation of SOCS3 stability in oral squamous cell carcinoma. PLoS One. 2016;11(7):e0158440. doi:10.1371/journal.pone.0158440
   PubMed Web of Science ®Google Scholar
• Song Q, Liu B, Li X, et al. miR-26a-5p potentiates metastasis of human lung cancer cells by regulating ITGβ8-JAK2/STAT3 axis. Biochem Biophys Res Commun. 2018;501(2):494–500. doi:10.1016/j.bbrc.2018.05.020
   PubMed Web of Science ®Google Scholar
• Looyenga BD, Hutchings D, Cherni I, et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012;7(2):e30820. doi:10.1371/journal.pone.0030820
   PubMed Web of Science ®Google Scholar
• Wu L, Guo L, Liang Y, et al. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Oncol Rep. 2015;34(6):3311–3317. doi:10.3892/or.2015.4279
   PubMed Web of Science ®Google Scholar
• Liu X, Chen B, You W, et al. The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway in non-small cell lung cancer. Cancer Lett. 2018;412:194–207. doi:10.1016/j.canlet.2017.10.017
   PubMed Web of Science ®Google Scholar
• Zhou J, Wu A, Yu X, et al. SIRT6 inhibits growth of gastric cancer by inhibiting JAK2/STAT3 pathway. Oncol Rep. 2017;38(2):1059–1066. doi:10.3892/or.2017.5753
   PubMed Web of Science ®Google Scholar
• Katsha A, Arras J, Soutto M, et al. AURKA regulates JAK2–STAT3 activity in human gastric and esophageal cancers. Mol Oncol. 2014;8(8):1419–1428. doi:10.1016/j.molonc.2014.05.012
   PubMed Web of Science ®Google Scholar
• Xu W, Chen G-S, Shao Y, et al. Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells. Cancer Lett. 2013;332(1):11–18. doi:10.1016/j.canlet.2012.12.030
   PubMed Web of Science ®Google Scholar
• Kim M-J, Nam H-J, Kim H-P, et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013;335(1):145–152. doi:10.1016/j.canlet.2013.02.010
   PubMed Web of Science ®Google Scholar
• Chen Z-M, Huang L, Li -M-M, et al. Inhibitory effects of isocryptotanshinone on gastric cancer. Sci Rep. 2018;8(1):1–10. doi:10.1038/s41598-017-17765-5
   PubMed Web of Science ®Google Scholar
• Zhang -R-R, Wang H, Hui N, et al. Enhanced antitumor effect of axitinib synergistic interaction with AG490 via VEGFR2/JAK2/STAT3 signaling mediated epithelial-mesenchymal transition in cervical cancer in vitro. Asian Biomed. 2013;7(1):39–49.
   Web of Science ®Google Scholar
• Li H, Lu Y, Pang Y, et al. Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway. Biomed Pharmacother. 2017;86:324–333. doi:10.1016/j.biopha.2016.12.036
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun. 2021;27:100328. doi:10.1016/j.ctarc.2021.100328
   PubMedGoogle Scholar
• Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21(13):2000–2008. doi:10.1038/sj.onc.1205260
   PubMed Web of Science ®Google Scholar
• Shen W, Chen C, Guan Y, et al. A pumpkin polysaccharide induces apoptosis by inhibiting the JAK2/STAT3 pathway in human hepatoma HepG2 cells. Int J Biol Macromol. 2017;104:681–686. doi:10.1016/j.ijbiomac.2017.06.078
   PubMed Web of Science ®Google Scholar
• Tang JJH, Thng DKH, Lim JJ, et al. JAK/STAT signaling in hepatocellular carcinoma. Hepat Onco. 2020;7:1.
   Web of Science ®Google Scholar
• Smirnova OV, Ostroukhova TY, Bogorad RL. JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression. World J Gastroenterol. 2007;13(48):6478. doi:10.3748/wjg.v13.i48.6478
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers. 2021;13(3):558. doi:10.3390/cancers13030558
   PubMed Web of Science ®Google Scholar
• Ostroukhova TY, Kulikov A, Rozenkrants A, et al. Overexpression of prolactin receptors during intrahepatic transplantation of RS1 rat cholangiocellular carcinoma cells. Bull Exp Biol Med. 2006;141(3):364–367. doi:10.1007/s10517-006-0172-6
   PubMed Web of Science ®Google Scholar
• Orlova A, Smirnova O, Turovetskiĭ V, et al. Effect of bromocriptin on prolactin receptor expression in liver cells after the common bile duct ligation. Biull Eksp Biol Med. 1998;126(7):52–55.
   PubMedGoogle Scholar
• Orlova A, Smirnov A, Smirnova O. The role of prolactin in the functional regulation of liver cells after the common bile duct ligation. Biull Eksp Biol Med. 1999;127(5):573–575.
   PubMedGoogle Scholar
• Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006;393(1):7–20. doi:10.1042/BJ20051578
   PubMed Web of Science ®Google Scholar
• Fernández-Martínez E, Pérez-álvarez V, Tsutsumi V, et al. Chronic bile duct obstruction induces changes in plasma and hepatic levels of cytokines and nitric oxide in the rat. Exp Toxicol Pathol. 2006;58(1):49–58. doi:10.1016/j.etp.2006.03.002
   PubMedGoogle Scholar
• Meng F, Yamagiwa Y, Ueno Y, et al. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006;44(6):1055–1065. doi:10.1016/j.jhep.2005.10.030
   PubMed Web of Science ®Google Scholar
• Wu F, Wu L, Zheng S, et al. The clinical value of hepatocyte growth factor and its receptor—c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 2006;38(7):490–497. doi:10.1016/j.dld.2006.03.007
   PubMedGoogle Scholar
• Imai Y, Kubota Y, Yamamoto S, et al. Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol. 2005;20(2):287–293. doi:10.1111/j.1440-1746.2004.03575.x
   PubMed Web of Science ®Google Scholar
• Bernichtein S, Kayser C, Dillner K, et al. Development of pure prolactin receptor antagonists. J Biol Chem. 2003;278(38):35988–35999. doi:10.1074/jbc.M305687200
   PubMed Web of Science ®Google Scholar
• Kirchhofer D, Lipari MT, Santell L, et al. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc Nat Acad Sci. 2007;104(13):5306–5311. doi:10.1073/pnas.0700184104
   PubMed Web of Science ®Google Scholar
• Gurbuz V, Konac E, Varol N, et al. Effects of AG490 and S3I‑201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL‑resistant prostate cancer cells in vitro. Oncol Lett. 2014;7(3):755–763. doi:10.3892/ol.2014.1795
   PubMed Web of Science ®Google Scholar
• Jorvig JE, Chakraborty A. Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity. Anticancer Drugs. 2015;26(2):160–166. doi:10.1097/CAD.0000000000000171
   PubMed Web of Science ®Google Scholar
• Wu K-J, Huang J-M, Zhong H-J, et al. A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. PLoS One. 2017;12(6):e0177123. doi:10.1371/journal.pone.0177123
   PubMed Web of Science ®Google Scholar
• Fu XQ, Chou JY, Li T, et al. The JAK 2/STAT 3 pathway is involved in the anti‐melanoma effects of atractylenolide I. Exp Dermatol. 2018;27(2):201–204. doi:10.1111/exd.13454
   PubMed Web of Science ®Google Scholar
• Ren Y, Huang S-S, Wang X, et al. Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway. Iran J Basic Med Sci. 2016;19(11):1245.
   PubMed Web of Science ®Google Scholar
• Hao Z, Sadek I. Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016;9:5495. doi:10.2147/OTT.S112242
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang W, Wang L, et al. Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway. Lab Investig. 2016;96(9):950–958. doi:10.1038/labinvest.2016.71
   PubMed Web of Science ®Google Scholar
• Hindupur SV, Schmid SC, Koch JA, et al. STAT3/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy. Int J Mol Sci. 2020;21(3):1106. doi:10.3390/ijms21031106
   PubMed Web of Science ®Google Scholar
• Joung YH, Na YM, Yoo YB, et al. Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway. Int J Oncol. 2014;44(3):883–895. doi:10.3892/ijo.2014.2250
   PubMed Web of Science ®Google Scholar
• Zhang H, Ye Y, Li M, et al. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene. 2017;36(15):2095–2104. doi:10.1038/onc.2016.367
   PubMed Web of Science ®Google Scholar
• Tsujita Y, Horiguchi A, Tasaki S, et al. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells. Oncol Rep. 2017;38(4):2197–2204. doi:10.3892/or.2017.5902
   PubMed Web of Science ®Google Scholar
• Chen C-L, Cen L, Kohout J, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008;7(1):1–12. doi:10.1186/1476-4598-7-78
   PubMed Web of Science ®Google Scholar
• Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–35. doi:10.1007/s00401-009-0619-8
   PubMed Web of Science ®Google Scholar
• Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wong CW, Yan M, et al. Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma. Cancer Lett. 2018;429:54–65. doi:10.1016/j.canlet.2018.04.040
   PubMed Web of Science ®Google Scholar
• Jensen KV, Cseh O, Aman A, et al. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One. 2017;12(12):e0189670. doi:10.1371/journal.pone.0189670
   PubMed Web of Science ®Google Scholar
• Zhang X, Yue P, Page BD, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Nat Acad Sci. 2012;109(24):9623–9628. doi:10.1073/pnas.1121606109
   PubMed Web of Science ®Google Scholar